Pfizer ( Pfizer )


Pfizer's picture

Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe, effective and affordable medicines and related health care services to the people who need them.

We have a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and we have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, like Alzheimer's disease and cancer.

Pfizer press release, blog etc

12/21/2017 - 06:56 Pfizer Inc. Announces Pricing and Early Results of its Tender Offer for its 5.750 per cent. Notes due 2021 and Related Solicitation of Consents
12/19/2017 - 17:27 U.S. FDA Approves Pfizers BOSULIF (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
12/19/2017 - 11:15 Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
12/18/2017 - 12:54 Pfizer Declares First-Quarter 2018 Dividend
12/15/2017 - 06:55 Pfizer Inc. Announces Expiration and Results of its Private Exchange Offer for its 6.500 per cent. Notes due 2038 and Related Tender Offer
12/14/2017 - 03:25 Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis
12/13/2017 - 21:12 Pfizer Announces FDA Approval of XELJANZ (tofacitinib) and XELJANZ XR for the Treatment of Active Psoriatic Arthritis
12/12/2017 - 23:37 Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Data Published in New England Journal of Medicine Demonstrate the Vaccines Immunogenicity
12/12/2017 - 23:18 FDA Approves New Pfizer Biosimilar
12/12/2017 - 13:36 U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofacitinib) Supplemental New Drug Application In Ulcerative Colitis By Three Months
12/08/2017 - 07:17 Talazoparib Significantly Extends Progression-Free Survival in Phase 3 EMBRACA Trial of Patients with Metastatic Breast Cancer
12/06/2017 - 08:46 Updated Data from Phase 3 Trial of IBRANCE (palbociclib) Plus Letrozole in ER+, HER2- Metastatic Breast Cancer Confirm Improvement in Progression-Free Survival
12/05/2017 - 09:55 Bristol-Myers Squibb and Pfizer Alliance Urge People to Tune in to AFib, Take Note of Stroke Risk
11/30/2017 - 21:22 Pfizer Enters into Agreement to Develop and Commercialize CRESEMBA (isavuconazole) in China and Asia Pacific Region
11/16/2017 - 14:55 Pfizer Receives FDA Approval for SUTENT (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
11/13/2017 - 12:11 Pfizer Names Albert Bourla Chief Operating Officer
10/29/2017 - 18:32 One Year Maintenance and Switching Data in Patients with Crohns Disease Support the Use of INFLECTRA* (infliximab CT-P13) in IBD1
10/16/2017 - 05:06 Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer